Posted by Michael Wonder on 20 Jul 2018
Sellas receives fast track designation from FDA for galinpepimut-S for the treatment of patients with multiple myeloma
20 July 2018 - Sellas Life Sciences today announced that the U.S. FDA has granted fast track designation to the Company’s lead asset, galinpepimut-S for the treatment of multiple myeloma.
Galinpepimut-S (GPS) is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumoor 1 protein, which is present in an array of tumour types.
The company reported final clinical and immunological data from a Phase 2 clinical trial for GPS in the treatment of high-risk multiple myeloma at the 44th Annual European Society for Blood and Marrow Transplantation meeting on 19 March 2018.
